FMP
Esperion Therapeutics, Inc.
ESPR
NASDAQ
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
2.32 USD
0.02 (0.862%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Sheldon L. Koenig
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.esperion.comexchange
NASDAQ
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
CIK
0001434868
ISIN
US29664W1053
CUSIP
29664W105
Address
3891 Ranchero Drive
Phone
734 887 3903
Country
US
Employee
240
IPO Date
Jun 26, 2013
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ESPR Financial Summary
CIK
0001434868
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
29664W105
ISIN
US29664W1053
Country
US
Price
2.32
Beta
0.95
Volume Avg.
5.7M
Market Cap
457.12M
Shares
-
52-Week
1.58-3.94
DCF
-0.02
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.46
P/B
-
Website
https://www.esperion.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ESPR News
It looks like there's no news available.
